[Correspondence] Finding gold in tumour immunotherapy

I read with interest the recent Editorial1 in The Lancet Oncology. The Editorial suggested that immunotherapy is being overhyped and offering false hope to patients with cancer. In the Editorial, advances in immunotherapy were likened to drug developments for EGFR and VEGF inhibitors, which were rolled out with great fanfare but eventually fell short of the initial promise.

http://ift.tt/2xMADdy